Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BsUFA III Meeting Improvements To Cut Requests, Improve Biosimilar Development Efficiency

Nov 03 2021

• By Derrick Gingery

Team efficiency — Quicker, targeted advice on from the FDA is expected to help speed biosimilar development. • Source: Alamy

Related Content

Remote Methods Drove Most US FDA Enforcement Actions In FY 2021

Oct 06 2021

FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office

Sep 11 2019

US FDA's On-Time Review Decision Rates Slip During The Pandemic, Especially For Biosimilars

Mar 17 2021

BsUFA III Expands Biosimilar Supplement Review Goals To Speed Approvals

Sep 22 2021

Related Companies

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Biosimilars User Fees Regulation Review Pathway BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window